Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBsAg + AS37 is a combination investigational vaccine formulation comprising **hepatitis B surface antigen (HBsAg)** and the experimental **AS37 adjuvant system** developed by GSK. HBsAg is a recombinant protein used as the antigenic component in hepatitis B vaccines, designed to elicit a protective immune response against hepatitis B virus infection. AS37 is a novel adjuvant system under investigation to enhance the immune response to the HBsAg antigen, potentially distinguishing its profile compared to other adjuvants like aluminum salt-based or AS04/AS03 systems. The vaccine is in early-stage clinical trials for safety and immunogenicity assessment in healthy adults aged 18-45 years for the prevention of hepatitis B[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HBsAg + AS37.